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BACKGROUND: Stromal cells are a functionally important component of human carcinomas. The aim of this study was to obtain and
characterise primary cultures of stromal cells from human carcinomas and the corresponding surrounding normal tissue.
METHODS: Primary stromal cell cultures from tumours of lung, oesophagus and pancreas were obtained using a mild tissue dissociation
method and a medium for culturing mesenchymal cells. Immunofluorescence staining and western blotting were used to analyse the
expression of differentiation markers and selected known oncoproteins in the cell cultures obtained.
RESULTS: A panel of stromal primary cultures was prepared from different human tumours and from matched normal cancer-free
tissues. The in vitro proliferative potential of tumour-associated fibroblasts was shown to be higher than that of matched normal
stromal cells. A mutational analysis of the TP53 and KRAS2 genes in a number of stromal cultures did not reveal known mutations in
most cells of the cultures studied. Western blot analysis showed that stromal cells of lung tumours were characterised by a statistically
significantly lower expression level of the p16 protein as compared with that in normal lung stromal cells. An important finding of our
study was that, according to immunofluorescence assay, a fraction of fibroblast-like vimentin-positive cells in some tumour and normal
stromal cell cultures expressed an epithelial marker – cytokeratins.
CONCLUSION: Proliferating stromal cells from the carcinomas studied proved to be genetically normal cells with altered expression
profiles of some genes involved in carcinogenesis, as compared with normal stromal cells. Epithelial-mesenchymal transition may lead
to the emergence of transdifferentiated fibroblast-like cells in tumour stroma and in the tumour-surrounding tissue.
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Virtually all carcinomas evolve as complex mixtures of genetically
altered epithelial cells and presumably genetically normal host
stromal cells such as fibroblasts, smooth muscle cells, vascular and
inflammatory cells (Mueller and Fusenig, 2004). The spatial and
temporal complexity of cancer stroma is now well recognised. It
has been shown that stromal alterations can precede malignant
progression of epithelial tumours (Bhowmick et al, 2004). The
alterations can include emergence of activated stromal fibro-
blasts (myofibroblasts) in the connective tissue surrounding
cancer cells in a majority of epithelial tumours. Several lines of
studies performed in vitro and in vivo indicated that the
proliferative and invasive potential of malignant epithelial cells
was modulated through heterotypic interactions with the me-
senchymally derived stromal microenvironment (Elenbaas and
Weinberg, 2001; Tlsty and Hein, 2001; Kalluri and Zeisberg, 2006).
Microenvironmental conditions within the tumour, induced by
activated stromal cells, such as disorganised vascular network,
increased interstitial fluid pressure and intratumoural hypoxia,
which hindered the efficient delivery and action of anticancer
drugs. Although tumour stromal cells might be an attractive target
for anticancer therapy, molecular differentiation of tumour-
associated fibroblasts and their activated signaling pathways are
still poorly studied.
One of the most powerful tools for deciphering molecular
mechanisms of cancer progression and understanding of tumour
intervention strategies are cell lines derived from human cancer
cells. It was shown that established human cancer cell lines
retained morphological, phenotypic and genetic characteristics of
the corresponding parental tumours (Wistuba et al, 1998, 1999).
We supposed that stromal cell cultures established from human
tumours might represent the corresponding tumour micro-
environment, thus providing a useful complement to cancer cell
lines in human neoplasia research.
In this study, we describe a preparation of a panel of stromal
cell cultures derived from several types of human tumours and
from morphologically normal, cancer-free tissue. We found that
common features of all tumour stromal cells were extended
replicative lifespan in culture and a higher Ki67 labeling index
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scompared with matched normal stromal cells. A mutational
analysis of the TP53 and KRAS2 genes in a number of stromal
cultures studied revealed that most cells were genetically normal.
An important finding of our studies is that, as shown by
immunofluorescence assay, a fraction of fibroblast-like cells in
some tumour and normal stromal cell cultures expressed both
epithelial and mesenchymal markers, cytokeratins and vimentin,
suggesting that these cells have undergone epithelial-mesenchymal
transition (EMT). Western blot analysis of differentiation markers
and known oncoproteins revealed heterogeneous patterns of their
expression that varied among individual cancer stromal cultures,
even of the same histological type. Stromal cells of lung tumours
were characterised by a statistically significantly lower expression
level of the p16 protein as compared with that in normal lung
stromal cells. A common feature of all the cultures was a low
content of the p53 protein that may be indicative of the wild-type
p53 in the cells analysed.
MATERIALS AND METHODS
Materials and cells
Unless otherwise specified, chemicals were obtained from Sigma-
Aldrich (St Louis, MO, USA). Sera and cell culture media were
obtained from Invitrogen (Invitrogen Corporation, Carlsbad, CA,
USA). Primary antibodies were as follows: mouse monoclonal D-8
anti-survivin, mouse monoclonal DO-1 anti-p53, mouse mono-
clonal DCS-6 anti-cyclin D1, rabbit polyclonal N-20 anti-p16,
rabbit polyclonal H-63 anti-N-cadherin, rabbit polyclonal H-108
anti-E-cadherin, rabbit polyclonal V-18 anti-TCF-3 (E2A), mouse
monoclonal 0411 anti-GAPDH (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), mouse monoclonal V9 anti-vimentin, mouse
monoclonal 1A4 anti-a-smooth muscle actin, mouse monoclonal
C-11 anti-pancytokeratin (Sigma-Aldrich), mouse monoclonal
L70G2 anti-SNAI I (Snail) (Cell Signaling, Danvers, MA, USA),
mouse monoclonal anti-Bcl-2 (Upstate, Lake Placid, NY, USA),
mouse monoclonal anti-Ki67 (clone MIB-1) and rabbit polyclonal
Z0622 anti-pancytokeratin from Dako (Dako, Carpinteria, CA, USA).
Secondary goat anti-mouse and anti-rabbit IgG antibodies
conjugated to HPR were obtained from Santa Cruz Biotechnology.
Secondary goat anti-mouse and anti-rabbit IgG antibodies
conjugated to Alexa Fluor 488 and Alexa Fluor 555 were obtained
from Molecular Probes (Eugene, OR, USA).
NCI-H23, A549 and MIA PaCa-2 human cancer cell lines were
obtained from American Type Cell Collection (ATCC, Manassas,
VA, USA) and maintained in Dulbecco’s modified Eagle’s medium/
Ham’s F12 (DMEM/F12, 1:1) containing 10% fetal calf serum,
2m ML -glutamine, 100Uml
–1 penicillin and 100mgml
–1 strepto-
mycin. A normal human lung embryonic fibroblast culture (LEF)
was kindly provided by Dr GT Sukhikh (Research Center of
Obstetrics, Gynecology, and Perinatology, Russian Academy of
Medical Sciences, Moscow, Russia). All cells were cultured at 371C
in humidified atmosphere of 95% air and 5% CO2.
Patients and tissue specimens
Surgical tumour specimens were obtained from a series of 20
patients with diagnosed cancer who have undergone complete
resection of tumours at the NN Blokhin Russian Cancer Research
Center (Moscow, Russia) and the AV Vishnevsky Institute of
Surgery (Moscow, Russia), between December 2004 and May 2006.
The final diagnosis was confirmed by hematoxylin-eosin staining
of paraffin blocks after the operation. None of the patients received
chemo- or radiotherapy before surgery. All tumour samples were
obtained after informed consent of the patients. The project
protocol was approved by the Institutional Review Boards at the
NN Blokhin Russian Cancer Research Center and the AV
Vishnevsky Institute of Surgery. Patient and tumour character-
istics are listed in Table 1.
Samples were dissected from central parts of the tumours and
from normal tissue adjacent to the resected region at the time of
surgery. Histological examination of tumour samples revealed that
more than 75% of the cells had been cancer epithelial cells. Normal
samples were histologically normal and looked microscopically
like carcinoma-free tissue specimens. The fresh tumour and
normal tissue samples were immediately transferred into sterile
Hank’s balanced salt solution (HBSS; Invitrogen) and stored
on ice.
Fibroblast culture preparation
All tissue samples were processed within the first 24h. Before
tissue dissociation, fat and necrotic areas were dissected from
surgical materials, and tissue samples were minced in a small
volume of cold HBSS into 1mm
3 pieces using sterile scissors.
Minced tissues were then dissociated with collagenase type A
Table 1 Characteristics of patients and patient tumours
Patient # Sex Age Histological classification TNM Stromal cell cultures
1 F 64 AD of lung T1N1M0 L1T, L1N
2 M 57 AD of lung T3N2M1 L2T, L2N
3 M 56 AD of lung T4N2M0 L3T, L3N
4 M 55 SCC of lung T4N0M0 L4T, L4N
5 F 41 SCC of lung T2N1M0 L5T, L5N
6 M 58 SCC of lung T4N0M0 L6T, L6N
7 M 56 SCC of lung T3N2M0 L7T, L7N
8 M 50 SCC of lung T2N0M0 L8T, L8N
9 M 66 AD of lung T1N2M0 L9T, L9N
10 M 54 SCC of lung T2N2M0 L10T, L10N
11 M 56 AD of lung T3N0M0 L11T, L11N
12 F 53 BAC of lung T2N0M0 L12T, L12N
13 M 16 Metastatic chondrosarcoma n/a L13T, L13N
14 M 59 AD of lung T1N0M0 L14T
15 M 66 SCC of lung T2N2M0 L15T
16 M 69 SCC of lung T3N0M0 L16T
17 F 42 SCC of oesophagus T2N2M0 E1T, E1N
18 F 34 CA of pancreas n/a P2T
19 M 62 AD of pancreas T3N0M0 P3T
20 M 51 AD of pancreas T3N1aM0 P4T
Abbreviations: AD¼adenocarcinoma; BAC¼bronchioloalveolar carcinoma; CA¼carcinoid; n/a¼data not available; SCC¼squamous cell carcinoma.
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s(1mgml
–1; Roche Applied Science, Penzberg, Germany), dispase
(1mgml
–1; Invitrogen) and deoxyribonuclease I (100unitsml
–1;
Sigma-Aldrich) at 371C with gentle agitation for 3–4h in HBSS
with 1% fetal calf serum. The dissociated cells were then filtered
using 100mm cell strainers (Becton Dickinson Labware, Franklin
Lakes, NJ, USA), and the cellular filtrate centrifuged at 250g for
5min. The cell pellet was resuspended in DMEM/F12 (1:1)
containing 10% fetal calf serum, 2mML -glutamine, 100Uml
–1
penicillin and 100mgml
–1 streptomycin, and viable cell counts
were determined by the Trypan blue exclusion test in a
hemocytometer. In all, 10
5 viable cells were plated on standard
uncoated Corning Costar 25-cm
2 flasks (Corning Incorporated,
Lowell, MA, USA). The culture medium was changed every second
day, and the cultures reached confluency in 10–12 days (passage
0). The cells were split 1:4 once a week. A majority of the stromal
cell cultures were frozen at passage 2. In all experiments, cells
between passages 4 and 6 were used.
Proliferation assay
Stromal cells were seeded at 10
3 cells per well in 96-well black plates.
The number of cells was determined daily over a 5-day period using
the Hoechst 33258 assay (Rago et al,1 9 9 0 )w i t haG E N i o sP r op l a t e
r e a d e r( T E C A N ,M a n n e d o r f ,S w i t zerland) at the excitation wave-
length of 360/35nm and detection wavelength of 460/10nm.
Mutational analysis
A QIAamp DNA Purification Kit (Qiagen, Valencia, CA, USA) was
used to isolate genomic DNA from stromal cells and control cancer
cell samples.
Exons 5 (211-bp fragment), 6 (182-bp fragment) and 7 (139-bp
fragment) of the TP53 gene were PCR amplified from genomic
DNA samples (see PCR primers in Supplementary Table 1). Briefly,
100ng of genomic DNA were used as a PCR template in a 50-ml
reaction mixture. PCR amplification was performed as follows:
3min at 951C, 1min at 641C, 1min at 721C, and then 29 cycles for
1min at 951C, 2min at 641C and 1min at 721C. The PCR products
were column purified using a QIAquick PCR Purification Kit
(Qiagen) and directly sequenced with dye terminator chemistry
using an ABI Prism 3100-Avant Genetic Analyser automatic DNA
sequencer (Applied Biosystems Inc, Foster City, CA, USA). The
same set of primers was used for PCR and the sequencing. As a
positive control for mutation of the TP53 gene, genomic DNA of
NCI-H23 (codon 246 mutation) and MIA PaCa-2 (codon 248
mutation) cancer cell lines were used.
Mutations at codon 12 of the KRAS2 gene were examined by a
slightly modified mutant-allele-specific amplification method, as
described by Yamada et al (1998). Briefly, 100ng of genomic DNA
were used as a PCR template in a 50-ml reaction mixture. PCR
amplification with wild-type primers (Supplementary Table 1) was
performed as follows: 3min at 941C, 2min at 621C, 1min at 721C,
and then 35 cycles for 1min at 941C, 2min at 621C and 1min at
721C. PCR with mutant-specific primers (Supplementary Table 1)
was performed using the same protocol except that the annealing
temperature was 681C. DNA samples were considered positive for
mutation of the KRAS2 gene when their PCR products were
identified as a 180-bp band in 1.5% agarose gel electrophoresis. As
a positive control for codon 12 mutation of the KRAS2 gene,
genomic DNAs of NCI-H23 (GGT4TGT), A549 (GGT4AGT) and
MIA PaCa-2 (GGT4TGT) cancer cell lines were used.
Western blot analysis
Cell lysates were prepared from subconfluent cultures. To this end,
cells were washed twice with cold PBS and lysed for 30min in
NP-40 lysis buffer (1% NP-40, 0.2% sodium deoxycholate, 200mM
NaCl, 100mM T r i s - H C l ,p H7 . 5 ,2m M EDTA, 1mM EGTA, 10mM NaF,
1m M Na3VO4,1 m M AEBSF, 100mgml
–1 aprotinin, 100mgml
–1
leupeptin and 100mgml
–1antipain) on ice. The protein concentration
in the lysates was determined using a Micro BCA protein assay kit
(Pierce, Rockford, IL, USA). Equal amounts of cell lysates (20mgo f
protein) were boiled in SDS sample buffer consisting of 1% SDS, 2%
2-mercaptoethanol, and 62mM Tris-HCl, pH 6.8, subjected to SDS
electrophoresis in 10–15% polyacrylamide minigels and then
electrotransferred to a PVDF Immobilon-P membrane (Millipore,
Bedford, MA, USA) using a Bio-Rad Trans-Blot SD cell (Bio-Rad
Laboratories, Hercules, CA, USA). After this, the membranes were
blocked with 5% skimmed milk in PBS-T (PBS containing 0.1% Tween
20) for 1h at room temperature, incubated in PBS-T containing 5%
s k i m m e dm i l ka n dt h er e l e v a n tp r i m a r ya n t i b o d yo v e r n i g h ta t4 1C
and finally washed three times with PBS-T. Mouse monoclonal anti-
GAPDH antibody (0411) was used as a loading control. After washing,
the membranes were incubated in PBS-T containing 5% skimmed
milk and goat anti-mouse or anti-rabbit antibody HRP conjugates
(Santa Cruz, 1:10000) for 1h at room temperature. The membranes
were finally washed with PBS-T, and specific signals were visualised
using an Immun-Star HRP Chemiluminescent detection kit (Bio-Rad)
and a Bio-Rad VersaDoc MP4000 imager station. Protein expression
levels were quantified by western blot densitometry, and individual
protein levels were normalised to GAPDH values.
Immunofluorescence
For immunofluorescence experiments, stromal cells were cultured
overnight on two-well chamber slides (Becton Dickinson Labware).
The cells were washed twice with cold PBS, fixed with 4%
paraformaldehyde in PBS for 30min at 41C, washed once with cold
PBS, permeabilised in PBS containing 0.5% Triton X-100 for
10min at room temperature, and then blocked overnight with 10%
normal goat serum (Invitrogen) in PBS at 41C. The blocked cells
were incubated with primary antibody in PBS containing 10%
normal goat serum for 45min at room temperature. After further
washes with 0.1% Tween 20 in PBS, Alexa Fluor 488 goat anti-
mouse IgG secondary antibody or Alexa Fluor 555 goat anti-rabbit
IgG (Molecular Probes) secondary antibody were applied for 1h.
After final washing, slides were incubated with DAPI (Molecular
Probes, 1mgml
–1 in PBS) to stain nuclei, or phalloidin -TRITC
(Sigma-Aldrich, 0.5mgml
–1 in PBS) to stain F-actin for 45min,
washed with PBS and finally mounted with Prolong Antifade
reagent (Molecular Probes). Slides were viewed the next day with a
Nikon TE2000U microscope equipped with epifluorescence optics
(Nikon Europe, Amstelveen, The Netherlands). Images were
captured with a cooled CCD camera (DS-5Mc, Nikon). All captured
images were imported into Photoshop 7.0 (Adobe Systems Inc.,
San Jose, CA, USA) as BMP files.
Statistical analysis
Data were analysed and presented as the mean±s.e.m. P-values
were determined by Student’s t-test, and Po0.05 was considered
statistically significant.
RESULTS
Mild dissociation of surgical specimens and the choice of culture
medium for preferential growth of primary mesenchymal cells
allowed us to reproducibly obtain morphologically homogenous
cultures of stromal cells from a number of human carcinomas, free
of contamination with epithelial cells (Figure 1). We have prepared
a collection of primary stromal cell cultures from human tumours
of various origin and localisation (Table 1). The collection
included:
(1) A panel of primary cell cultures of lung cancer stromal cells
from 15 patients with a confirmed diagnosis of NSCLC (cell
Stromal cell cultures from human carcinomas
EP Kopantzev et al
1535
British Journal of Cancer (2010) 102(10), 1533–1540 & 2010 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
scultures L1T-L12T and L14T-L16T). The corresponding
stromal cell cultures of unaffected lung tissue from 12 of
these patients were also established (cell cultures L1N-L12N).
The age of the patients varied from 41 to 69 years (with the
mean age of 57 years), and the stages of disease – between IA
and IV.
(2) Primary stromal cell cultures from primary chondrosarcoma
metastasis in lung and from adjacent healthy tissue (cell
cultures L13T and L13N, respectively) prepared from one
patient.
(3) Primary stromal cell cultures (cell cultures E1T and E1N)
prepared from one patient with a confirmed diagnosis of
oesophagus SCC.
(4) Primary tumour stromal cell cultures (cell cultures P2T–P4T)
prepared from three patients with a confirmed diagnosis of
pancreatic cancer.
(5) Primary stromal cell culture P1P prepared from the pancreas
of a patient operated on for chronic pancreatitis.
Cell morphology and proliferative potential of stromal cell
cultures
The cultured stromal cells appeared morphologically as typical
fibroblasts at all stages of culturing. The original primary cultures
(passage 0) contained not only fibroblast-like cells, but also
macrophages and individual epithelial cells or even their clusters
(data not shown). However, after passage 2–3, the primary
cultures appeared as morphologically homogeneous populations of
fast-growing fibroblast-like cells. Proliferating cells in established
cultures had a characteristic spindle-like shape with elongated
projections. The cells became growth arrested at confluence.
Stromal cells from various tissues had no significant differences in
terms of cell morphology (Figure 1A–F). To determine the
proliferative potential of the established stromal cell cultures, cells
were grown with a subculturing ratio of 1:4 for a period of several
months, until they have reached their proliferative senescence. The
maximum number of passages varied from 7 to 25, which
corresponds to approximately 14–50 cell divisions, as observed
from Table 2. The average number of cell doublings for normal
stromal lung cells was 32.6±12.6, whereas for tumour stromal lung
cells it was somewhat higher (39.2±7.6). Remarkably, in all the
analysed pairs of normal vs tumour stromal cell cultures, the
proliferation capacity of the tumour stroma was higher than that of
matched normal cell culture (Table 2, P¼0.003, paired t-test). To
estimate cell proliferation rates of tumour and normal stromal
cultures, we used staining with Hoechst 33258 to plot cell growth
curves at passage 6 of culturing. Except only one case (patient 13,
metastatic chondrosarcoma in lung), the proliferation rate of
tumour stromal cells exceeded that of normal cells. The cells of
L2T and L2N stromal cultures proliferated with similar rates
(Supplementary Figure 1a).
We also performed immunofluorescent staining of tumour and
normal cell cultures (L2T, L2N, L6T, L6N, L7T, L7T, L15T, E1N,
E1T, P1P, P3T, P4T) with antibodies to the nuclear proliferation
antigen Ki67 (Supplementary Figure 1b). The relative content of
Table 2 Characteristics of stromal cell cultures
Stromal cell cultures Replicative lifespan of cells in vitro
a Vimentin-positive cells in cultures
b Cytokeratin-positive cells in cultures
b
Tumour Normal Tumour Normal Tumour Normal Tumour Normal
L1T L1N 20 (40) 18 (36) 100% 100% 40.1% 40.1%
L2T L2N 21 (42) 19 (38) 100% 100% 5.7% 5.3%
L3T L3N 19 (38) 14 (28) ND ND ND ND
L4T L4N 25 (50) 24 (48) ND ND ND ND
L5T L5N 20 (40) 18 (36) 100% 100% 1.6% 2.7%
L6T L6N 18 (36) 14 (28) 100% 100% 40.1% 40.1%
L7T L7N 15 (30) 8 (16) 100% 100% 2.9% 40.1%
L8T L8N 18 (36) 7 (14) 100% 100% ND ND
L10T L10N 17 (34) 14 (28) ND ND ND ND
L13T L13N 29 (58) 27 (54) 100% 100% 40.1% 40.1%
L14T n/a 17 (34) n/a ND ND ND ND
L15T n/a 20 (40) n/a ND ND ND ND
L16T n/a 16 (32) n/a 100% n/a 2.2% n/a
E1N E1T 21 (42) 11 (22) ND ND ND ND
P3T n/a 13 (26) n/a 100% n/a 40.1% n/a
Abbreviations: n/a¼data not available; ND¼not done.
aLimit of passages (maximal number of cell doublings) in vitro with subcultivation ratio of 1:4.
bPercentage of total cells.
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Figure 1 Morphology of normal and tumour stromal cells. Representa-
tive microscopic fields showing normal L2N (A), L5N (C) and tumour L2T
(B), L5T (D), L16T (E) P3T (F) stromal cells. Original magnification  100
(phase contrast).
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sKi67-positive cells in the analysed cultures varied between 28 and
78%. The Ki67 labeling index for tumour stromal cells was
statistically significantly higher than that for matched normal
stromal cells (Supplementary Figure 1c).
Mutational analysis of TP53 and KRAS2
To determine the genetic status of cells in the obtained stromal
cultures, we isolated genomic DNA from L5N, L5T, L6N, L6T,
L13N, L13T, L15T, E1N, E1T, P1P, P3T and P4T cells, and then
analysed the TP53 gene (exons 5–7) by direct DNA sequencing
and the KRAS2 gene (codon 12) using highly sensitive mutant-
allele-specific amplification. We did not detect any mutations in
the TP53 gene of tumour stromal cells (L5T, L6T, L13T, L15T, E1T,
P3T, P4T), as well as of normal stromal cells (L5N, L6N, L13N,
E1N, P1P). Similarly, no activating mutations were revealed in
codon 12 of the KRAS2 gene (Supplementary Figure 2) in both
tumour and normal stroma cells. These results suggest that
stromal cells of the tumours studied are generally genetically
normal.
Detection of epithelial-like cells in stromal cell cultures
To define cell types within the prepared stromal cultures, we
analysed the expression of vimentin as a common mesenchymal
cytoskeletal marker. An immunofluorescence analysis performed
using monoclonal antibodies V9 on cells of normal (L1N, L2N,
L5N, L6N, L7N, L8N, L13N) and tumour stromal cultures (L1T,
L2T, L5T, L6T, L7T, L8T, L13T, L16T, P3T) revealed that
practically all these cultures were positive for expression of
intracellular vimentin suggesting that they belonged to a
mesenchymal cell type (Table 2 and Figure 2D and J).
We used monoclonal anti-pancytokeratin antibodies C-11 to
analyse cells expressing cytokeratins, markers of cells of epithelial
origin. Surprisingly, we detected cytokeratin-positive cells in a
number of cultures of normal (L2N and L5N) and tumour stromal
cells (L2T, L5T, L7T, L16T). The total content of cytokeratin-
positive cells in other analysed cell cultures (L1N, L1T, L6N, L6T,
L7N, L13N, L13T and P3T) was rather low – o0.1% of the total
number of cells (Table 2). The detected cytokeratin-positive cells had
an elongated morphological appearance characteristic of fibroblasts
(Figure 2). To further characterise the cytokeratin-positive cells, we
ABC
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Figure 2 Indirect immunofluorescence staining of tumour (L2T, A–F) and normal (L2N, G–L) stromal cells. The L2T tumour stromal cells stained with
mouse anti-pancytokeratin antibody (A), phalloidin –TRITC (B), mouse anti-vimentin antibody (D) and with rabbit anti-pancytokeratin antibody (E).
(C) merge of A and B;( F) merge of D and E. The L2N normal stromal cells stained with mouse anti-pancytokeratin antibody (G), phalloidin –TRITC (H),
mouse anti-vimentin antibody (J) and with rabbit anti-pancytokeratin antibody (K). (I) merge of G and H;( L) merge of J and K. All slides were
counterstained with DAPI. Original magnification  200.
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pancytokeratin antibodies and monoclonal anti-vimentin anti-
bodies V9. Figure 2 shows the result of this staining in L2N and
L2T cell cultures, clearly evidencing that cells expressing cyto-
keratin are also vimentin-positive. Similar results were obtained
for stromal cell cultures L5N, L5T, L7T and L16T (data not shown).
Protein expression patterns of stromal cells
We performed western blot analysis on cellular extracts from cells
obtained at early stages of culturing (passages 4–6). All tumour
and normal stromal cells expressed the mesenchymal protein
marker vimentin (Figure 3). The protein level of vimentin
expression was approximately the same for all cell culture extracts,
consistent with the results of a previously performed immunos-
taining. Western blot analysis of cellular extracts with monoclonal
antibodies C-11 allowed us to estimate the expression of
cytokeratins in cells of stromal cultures, including some of those
not studied by immunofluorescence (Figure 3). In a number of
normal (L2N, L3N, L4N, L5N, L7N and L8N) and tumour (L2T,
L3T, L5T, L7T and L16T) cell cultures, expression of cytokeratins
was detected, suggesting the presence of cytokeratin-positive cells.
In the case of oesophagus tumour, expression of cytokeratins was
detected in cells of the normal stromal culture and was relatively
low in the tumour stroma. In pancreatic stromal cultures,
expression of cytokeratins was detected in cells prepared from a
patient with chronic pancreatitis and a patient with carcinoid of
pancreas. In two cases with ductal adenocarcinoma of pancreas,
stromal cells were found to be cytokeratin-negative. It is worth
noting that cytokeratin expression was detected in two cell cultures
(L7N and P2T) that seemed cytokeratin-negative from fluorescent
immunostaining.
The other marker of epithelial cells, E-cadherin, was not
expressed in all stromal cultures analysed. Interestingly, at the
same time practically all cultures showed low or moderate
expression of N-cadherin (Figure 3).
To check for possible presence of myofibroblast cells in the
prepared stromal cultures, we used a western blot analysis of cell
extracts with monoclonal antibody 1A4 against a -smooth muscle
actin (a-SMA) – a protein marker of myogenic fibroblast
differentiation (Figure 3). We failed to observe the expected
enhanced expression of a-SMA in tumour stromal cell cultures:
a-SMA was expressed in both tumour and normal stromal cells.
Moreover, in some cases (L6N, L8N, L10N, L11N and E1N) the
expression of a-SMA was even higher in normal stromal cells than
in the corresponding tumour stromal cells. The highest level of
a-SMA was detected in the stromal culture prepared from the
pancreatitis tissue specimen and in all tumour stromal cultures of
pancreas cancer. This observation is consistent with the data on
frequent development of tumour desmoplasia in this organ.
Finally, we analysed the expression patterns of seven important
cellular oncoproteins (survivin, p53, cyclin D1, p16, BCL-2, SNAI I
and TCF-3) whose expression levels in various human tumours are
frequently different from the levels in normal cells (Figure 3). In
tumour stromal cell cultures L1T, L4T, L5T, L6T, L9T and L13T,
the level of survivin was lower than in the corresponding normal
stroma cell cultures. Interestingly, in some of the normal cell
cultures the expression level of survivin was close to that in cells of
lung adenocarcinoma NCI-H23. In other cases, the level of survivin
expression was rather low, although slightly increased in a number
of tumour stroma cell cultures (L2T, L3T, L7T, L8T, L11T and
L12T) as compared with normal stromal cells. We did not reveal
any significant correlation between the expression levels of
survivin and cytokeratins in the analysed cell cultures. In several
tumour stromal cell cultures (L1T, L5T and L7T), the expression
level of the tumour suppressor p53 protein was slightly higher than
in normal stromal cells, whereas in other cultures (L6T, L9T and
L13T) it was, in contrast, somewhat lower. Nevertheless, the level
of p53 in both normal and tumour stromal cells was rather
low suggesting the absence of p53 mutations in the cell cultures
studied. Similarly, the level of cyclin D1 protein in tumour
stromal cell cultures was higher (L2T, L3T, L5T, L7T and L12T) or
lower (L6T, L8T, L9T, L10T and L13T) than in the corresponding
normal stromal cell cultures. Interestingly, in the case of
stromal cells derived from a surgical tissue specimen of squamous
cell cancer of oesophagus, the cyclin D1 expression in
tumour stromal cells was downregulated as compared with that
observed in normal stromal cells. The western blot analysis showed
that the expression level of p16 in tumour stromal cells had often
been lower than in normal stromal cultures (Figure 3). The
expression level of the antiapoptotic protein Bcl-2 in the stromal
cultures obtained was heterogeneous: in some tumour stromal
cultures (L2T, L3T, L7T, L8T, L10T, L11T and E1T) the Bcl-2
expression was upregulated, whereas in some others (L1T, L4T,
L5T, L9T and L13T) downregulated. Interestingly, stromal cells of
all tumour and normal cultures expressed detectable quantities of
the SNAI I (Snail) and TCF-3 (E2A) proteins known to be
transcriptional repressors of the CDH1 gene and potential inducers
of EMT.
Finally, we estimated the expression levels of the proteins
under study in 16 cultures of lung tumour stromal cells and
in 13 cultures of normal lung stromal cells (Supplementary Figure
3). It was shown that of 12 proteins studied only p16 was
statistically significantly (P¼0.02, two-tailed unpaired t-test)
downregulated in lung tumour stroma as compared with normal
lung stroma.
GAPDH
Cyclin D1
p16
p53
Survivin
Bcl-2
TCF-3
SNAI 1
α-SMA
N-cadherin
E-cadherin
Cytokeratin
Vimentin
P4T
P3T
P2T
P1P
E1T
E1N
LEF
L16T
L15T
L14T
L13T
L13N
L12T
L12N
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L9T
L9N
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L7T
L7N
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L1T
L1N
Markers
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Figure 3 Western blot analysis of vimentin, cytokeratins, E-cadherin, N-cadherin, a-SMA, SNAI I (Snail) protein, TCF3 (E2A), Bcl-2, survivin, p53, p16 and
cyclin D1 expression in tumour and matched normal stromal cells. Mouse monoclonal anti-GAPDH antibody was used as a loading control. NCI-H23 – the
human lung adenocarcinoma NCI-H23 cell line; M – protein molecular weight marker (Santa Cruz).
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Cancer cell lines derived from human tumours are an extremely
important research tool for understanding basic tumour biology and
tumour intervention strategies. It was shown that established human
cancer cell lines retain morphological, phenotypic and genetic
characteristics of their corresponding parental tumours (Wistuba
et al, 1998, 1999). We assumed that stromal cell cultures established
from human tumours might be representative of the corresponding
tumour microenvironment thus providing a useful complement to
cancer cell lines in human neoplasia research. In this study, we
describe preparation of a panel of stromal cell cultures derived from
several types of human tumours and from normal cancer-free tissue.
A majority of these cultures were derived from surgically resected
primary tumours of lung, but the panel includes also stromal cell
cultures prepared from oesophagus and pancreas cancer tissues.
Stromal cells from tumours of different tissues had no significant
differences in terms of cell morphology. Microscopically, all
established stromal cultures after 3–4 passages grew as a monolayer
of cells with fibroblast-like appearance, devoid of normal or
malignant epithelial cells. Several lines of evidence suggest that
stromal cell senescence can greatly contribute to age-related
pathologies including cancer (Parrinello et al, 2005). But in all our
experiments, stromal cells derived from normal part of the resected
lung tumour tended to senesce faster (after fewer population
doublings) than cells from tumour part. Along with increased
replicative lifespan, tumour stromal cells were characterised by
higher values of the Ki67 index relative to normal stromal cultures.
The cell proliferation curves also suggest that tumour stromal cells
proliferate more rapidly than normal cells, at least at culture
passages 4–6. All these data show that the in vitro proliferative
potential of tumour-associated fibroblasts is higher than that of
their matched normal cells. It is assumed that at least in some cases
the intratumoural fibroblast population has a higher replicative
capacity than surrounding peritumoural stromal cells.
Epithelial to mesenchymal transition is a fundamental biological
process in which epithelial cells lose their polarity and adopt
fibroblast-like morphology appropriate for migration (Thiery,
2002; Grunert et al, 2003). In recent papers, active EMT processes
were described for lung epithelial cells under different pathological
conditions such as lung fibrosis and cancer (Iwano et al, 2002; Kim
et al, 2006). We also found possible signs of an EMT process in the
established lung tumour and matched normal stromal cell cultures.
In particular, generally quite homogeneous mesenchymal vimen-
tin-positive cells in all examined cultures contained a portion of
cytokeratin-positive cells. These cells persisted in populations of
both tumour and normal stromal cells (Figure 3). The double-
positive cells might well emerge as a result of an EMT process in
tumours and surrounding tissues. Cytokeratin-positive cells with a
fibroblast-like phenotype in the tissue-surrounding dissected
tumours may also be a sign of a high incidence of field
cancerisation in the upper aerodigestive tract of lung cancer
patients. The source of these cytokeratin-positive fibroblast-like
cells remains uncertain. They can originate from transdifferen-
tiated normal pulmonary epithelial cells as described for
pathological pulmonary fibrogenesis (Iwano et al, 2002; Kim
et al, 2006). The lack of mutations in the TP53 and KRAS2 genes in
a number of tumour stromal cultures analysed supports this
hypothesis. The tumour cells can also undergo EMT during their
progression toward the final metastatic phenotype (Shintani et al,
2008). Both possibilities require additional experiments that are
currently under way.
Moreover, one cannot exclude the possibility that stromal cells
in the cultures obtained may undergo the reverse process,
mesenchymal-to-epithelial transition (MET), because of which
epithelial cells with acquired mesenchymal properties can
recapitulate the initial epithelial state (Wells et al, 2008).
Detectable quantities of the SNAI I (Snail) and TCF-3 (E2A)
proteins in tumour and normal stromal cultures may also indicate
active EMT/MET processes both in tumour stroma and surround-
ing presumably normal tissue.
To better characterise the prepared stromal cell cultures, we
used western blot analysis to determine the expression profiles of
some proteins involved in tumour cell differentiation and in
different stages of malignant transformation and tumour progres-
sion. We observed practically homogeneous expression of
vimentin in all stromal cultures obtained. These cultures were
also E-cadherin negative, which suggests the lack of contamination
with epithelial tissue. An expression of a-SMA that reflects
activation and myogenic differentiation of stromal fibroblasts
(Oda et al, 1990; Rønnov-Jessen et al, 1995; Rønnov-Jessen and
Petersen, 1996) was also detected in most of tumour and normal
stromal cultures and was the highest in the pancreas-derived
stromal cells. Particularly interesting in our experiments was the
observation of a very heterogeneous expression pattern of
cytokeratin proteins in tumour and normal stromal cells. This
finding may reflect active EMT in tumour and normal tissue in the
lung of cancer patients. Moreover, the N-cadherin expression
revealed in tumour and normal stromal cells may suggest an
E-cadherin/N-cadherin switch, which is often a characteristic of
EMT (Hazan et al, 2004). In addition, the detection of survivin
expression in prepared stromal cell cultures from lung tumours
and from matched normal lung tissue was also an unexpected
result. In some stromal cell cultures, the survivin level may be
similar to that in the established tumourigenic lung adenocarci-
noma NCI-H23 cell line. Survivin expression is usually undetect-
able in most normal adult tissues, but survivin was identified as a
tumour-associated protein highly expressed in a wide range of
human carcinoma cells including lung (Monzo et al, 1999; Oshita
et al, 2004). Several mechanisms have been suggested to account
for this ‘overexpression’, one of them being the loss of the p53
tumour suppressor protein that inhibits transcription of the
survivin gene in normal cells (Xia and Altieri, 2006; Altieri, 2008).
Recently, inactivating mutations in the p53 tumour suppressor
gene have been found in cancer stromal cells of prostate and breast
tumours (Hill et al, 2005; Kiaris et al, 2005). However, we did not
find here mutations in TP53 or activating mutations in the KRAS2
gene of stromal cells from lung, oesophagus and pancreas
tumours. We showed also that the level of the p53 protein in all
but one analysed stromal cultures was relatively low suggesting the
wild-type status of p53 in most cultures (Carbone et al, 1994;
Toyooka et al, 2003), and that the survivin level did not correlate
with the level of p53. Therefore, inactivation of the p53 function
can hardly explain the survivin level enhancement. An interesting
suggestion may be that survivin expression is being changed in the
course of the above mentioned EMT, considering that EMT
induction leads in some cases to the emergence of cells with the
phenotype of stem cells (Mani et al, 2008). Thus, high level of
survivin may be a signature of some epigenetic or genetic changes
occurring in host cells and inherited by their cell descendants. This
interesting effect needs further investigation.
Summarising, a panel of stromal cell cultures from different
human carcinomas and from matched normal cancer-free tissue
was established. Using proliferating cell cultures of this panel, we
showed that tumour stromal cells had an extended replicative
lifespan and a proliferative potential in culture compared with
matched normal stromal cells. Double immunofluorescence and
western blot analysis of differentiation markers revealed a fraction
of vimentin/cytokeratin double-positive cells in some established
tumour and normal cultures. Thus, this study provides a new
evidence of the EMT or MET processes in tumour and normal lung
tissue of cancer patients. A western blot analysis of selected known
oncoproteins revealed a complex pattern of their expression with a
common feature – a low level of the p53 protein, indicating that it
is the wild-type protein. Unexpectedly, quite a proportion of
stromal cells were shown to express high level of survivin, which is
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scharacteristic of embryonic and tumour cells. Established primary
cultures can serve as a valuable source for isolation and
characterisation of different stromal cell populations.
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